Compare Teucrium Soybean Fund (SOYB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teucrium Soybean Fund vs TransMedics Group Inc — how do they compare? Teucrium Soybean Fund trades at $25.05, while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Teucrium Soybean Fund is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SOYB | TMDX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $26.28 | $150.42 |
52-Week Low | $21.46 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOYB trades at $25.24, up 0.28% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent news highlights agricultural sector tailwinds from China's crop purchase pledge, though geopolitical risks from Middle East tensions pose headwinds.
The outlook hinges on sector-specific catalysts like export demand, but absent financial data obscures valuation. Risks include commodity volatility and geopolitical spillovers. Investors require updated SEC filings to assess profitability and growth prospects amid mixed technical signals.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
